Towards Healthcare
Liver Cancer Drugs Market Size Envisioned at USD 9.94 Billion by 2032

Liver Cancer Drugs Market Size Envisioned at USD 9.94 Billion by 2032

The report covers Liver Cancer Drugs Market Size and Companies such as Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Merck KGaA, Pfizer Inc., Eisai Inc., Eli Lilly and Company and F. Hoffmann-La Roche Ltd. offering a range of therapies. The market is segmented by drug class, including chemotherapy, targeted therapy, immunotherapy and others. Distribution channels include hospitals, clinics, retail pharmacies and online pharmacies. The report offers the value (in USD Billion) for the above segments.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Liver Cancer Drugs Market Assessment

  • Overview
  • Global Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Targeted Therapy 
      • Bevacizumab
      • Cabozantinib
      • Lenvatinib
      • Ramucirumab
      • Regorafenib
      • Sorafenib
      • Other Targeted Therapies
    • Immunotherapy 
      • Atezolizumab with Bevacizumab
      • Nivolumab with Ipilimumab
      • Pembrolizumab
      • Durvalumab with Tremelimumab
      • Other Immunotherapies
    • Chemotherapy 
      • Gemcitabine
      • Oxaliplatin
      • Cisplatin
      • Doxorubicin
      • 5-fluorouracil
      • Capecitabine
      • Mitoxantrone
      • Other Chemotherapies
  • Global Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • South America

North America Liver Cancer Drugs Market Assessment

  • Overview
  • North America Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Targeted Therapy 
      • Bevacizumab
      • Cabozantinib
      • Lenvatinib
      • Ramucirumab
      • Regorafenib
      • Sorafenib
      • Other Targeted Therapies
    • Immunotherapy 
      • Atezolizumab with Bevacizumab
      • Nivolumab with Ipilimumab
      • Pembrolizumab
      • Durvalumab with Tremelimumab
      • Other Immunotherapies
    • Chemotherapy 
      • Gemcitabine
      • Oxaliplatin
      • Cisplatin
      • Doxorubicin
      • 5-fluorouracil
      • Capecitabine
      • Mitoxantrone
      • Other Chemotherapies
  • North America Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

Europe Liver Cancer Drugs Market Assessment

  • Overview
  • Europe Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Targeted Therapy 
      • Bevacizumab
      • Cabozantinib
      • Lenvatinib
      • Ramucirumab
      • Regorafenib
      • Sorafenib
      • Other Targeted Therapies
    • Immunotherapy 
      • Atezolizumab with Bevacizumab
      • Nivolumab with Ipilimumab
      • Pembrolizumab
      • Durvalumab with Tremelimumab
      • Other Immunotherapies
    • Chemotherapy 
      • Gemcitabine
      • Oxaliplatin
      • Cisplatin
      • Doxorubicin
      • 5-fluorouracil
      • Capecitabine
      • Mitoxantrone
      • Other Chemotherapies
  • Europe Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

Asia Pacific Liver Cancer Drugs Market Assessment

  • Overview
  • Asia Pacific Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Targeted Therapy 
      • Bevacizumab
      • Cabozantinib
      • Lenvatinib
      • Ramucirumab
      • Regorafenib
      • Sorafenib
      • Other Targeted Therapies
    • Immunotherapy 
      • Atezolizumab with Bevacizumab
      • Nivolumab with Ipilimumab
      • Pembrolizumab
      • Durvalumab with Tremelimumab
      • Other Immunotherapies
    • Chemotherapy 
      • Gemcitabine
      • Oxaliplatin
      • Cisplatin
      • Doxorubicin
      • 5-fluorouracil
      • Capecitabine
      • Mitoxantrone
      • Other Chemotherapies
  • Asia Pacific Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

Middle East and Africa Liver Cancer Drugs Market Assessment

  • Overview
  • Middle East and Africa Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Targeted Therapy 
      • Bevacizumab
      • Cabozantinib
      • Lenvatinib
      • Ramucirumab
      • Regorafenib
      • Sorafenib
      • Other Targeted Therapies
    • Immunotherapy 
      • Atezolizumab with Bevacizumab
      • Nivolumab with Ipilimumab
      • Pembrolizumab
      • Durvalumab with Tremelimumab
      • Other Immunotherapies
    • Chemotherapy 
      • Gemcitabine
      • Oxaliplatin
      • Cisplatin
      • Doxorubicin
      • 5-fluorouracil
      • Capecitabine
      • Mitoxantrone
      • Other Chemotherapies
  • Middle East and Africa Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

South America Liver Cancer Drugs Market Assessment

  • Overview
  • South America Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Targeted Therapy 
      • Bevacizumab
      • Cabozantinib
      • Lenvatinib
      • Ramucirumab
      • Regorafenib
      • Sorafenib
      • Other Targeted Therapies
    • Immunotherapy 
      • Atezolizumab with Bevacizumab
      • Nivolumab with Ipilimumab
      • Pembrolizumab
      • Durvalumab with Tremelimumab
      • Other Immunotherapies
    • Chemotherapy 
      • Gemcitabine
      • Oxaliplatin
      • Cisplatin
      • Doxorubicin
      • 5-fluorouracil
      • Capecitabine
      • Mitoxantrone
      • Other Chemotherapies
  • South America Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

Company Profiles

  • Bayer AG
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Eisai Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.

Conclusion & Recommendations

  • Insight Code: 5146
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: April 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a dedicated market research professional with over 2 years of experience in the healthcare industry. Specializing in healthcare market research, she brings valuable expertise in analyzing market trends, evaluating industry dynamics, and providing actionable insights to help businesses stay ahead in a competitive market.

Throughout her career, Deepa has focused on delivering in-depth research on various healthcare segments, including pharmaceuticals, biotechnology, and healthcare services. She excels in identifying emerging opportunities, assessing market risks, and understanding regulatory changes that impact the healthcare sector.

Her ability to synthesize complex data and translate it into clear, concise recommendations makes her a key contributor to successful strategic decision-making. Her work helps organizations better understand consumer behavior, market demands, and the regulatory landscape, facilitating informed business strategies.

With a passion for healthcare research and a commitment to excellence, Deepa continues to provide businesses with the market intelligence they need to thrive in an increasingly complex healthcare environment. Her insights are critical for companies seeking to navigate the evolving healthcare landscape and optimize their market positioning.

FAQ's

In the upcoming years, the liver cancer drugs market is anticipated to rise significantly due to factors like increased research and development, an expanding patient base, and an emphasis on personalized therapy.

Some major obstacles to the approval of new drugs are as follows: Safety-related issues: Carefully assessing the possible adverse effects of novel medications is necessary. Authorities that oversee cost-effectiveness consider the potential advantages of a treatment about its cost.

Despite recent progress, liver cancer treatment still needs a great deal of improvement. These unfulfilled needs include: improved medications for advanced hepatic carcinoma decreased adverse effects and increased efficacy, early identification, and diagnosis.

Global Cancer Observatory, American Liver Foundation, World Health Organization, National Institute of Health.

Warning: include(report-detail-graphs.php): failed to open stream: No such file or directory in /home/thealthcre/public_html/report-toc.php on line 515

Warning: include(): Failed opening 'report-detail-graphs.php' for inclusion (include_path='.:/opt/cpanel/ea-php74/root/usr/share/pear') in /home/thealthcre/public_html/report-toc.php on line 515